Gain Therapeutics Begins GT-02287 Phase 1b Extension Study Allowing Participants To Continue Treatment For Additional Nine Months

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule

The Phase 1b study enrolled 21 subjects and the last participants will complete 90 days of dosing in December 2025

Early results from the Phase 1b study to be presented at the International Congress of Parkinson's Disease (PD) and Movement Disorders in October

BETHESDA, Md., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the start of the Phase 1b extension study allowing participants to continue treatment for an additional nine months. More than half of the participants have agreed to continue treatment.

The Phase 1b study enrolled 21 participants and is expected to complete in December 2025. Early data from the Phase 1b study will be presented on October 7, 2025, at the International Congress of Parkinson's Disease and Movement Disorders® in Honolulu, HI.

Additional 90-day analysis from participants enrolled as of June 30, 2025, including functional changes scored according to the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) as well as biomarker data from cerebrospinal fluid and blood, will be available as expected in Q4 2025.